Dabrowska M, Prokopowicz J, Kemona H, Kretowska J, Kulik S, Głuszczak M
Department of Laboratory Clinical Diagnostics, Medical School, District Oncological Center, Białystok, Poland.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(5):641-6.
Serum antithrombin III and alpha-2-plasmin inhibitor concentrations has been evaluated in 26 patients with lung carcinoma. We observed a twofold decrease in antithrombin III level and no differences between test and control groups in alpha-2-plasmin inhibitor concentrations. Evidently, the decreased antithrombin III level may reflect its consumption because of enhanced plasma thrombin activity, whereas normal alpha-2-plasmin inhibitor may result in no induction of secondary fibrinolysis followed by the stimulation of the coagulation system or no conditions for primary increased fibrinolysis. It seems possible, that the antithrombin III level in the serum may at least partly reflect the tendency for hypercoagulability and spreading of cancer.
对26例肺癌患者的血清抗凝血酶III和α-2-纤溶酶抑制剂浓度进行了评估。我们观察到抗凝血酶III水平下降了两倍，而α-2-纤溶酶抑制剂浓度在试验组和对照组之间没有差异。显然，抗凝血酶III水平降低可能反映了由于血浆凝血酶活性增强导致的消耗，而正常的α-2-纤溶酶抑制剂可能不会引发继发性纤维蛋白溶解，随后也不会刺激凝血系统，或者不存在原发性纤维蛋白溶解增加的条件。血清中的抗凝血酶III水平似乎至少部分反映了癌症高凝倾向和扩散情况。
